Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines

References

• PorterKBabikerABhaskaranKDeterminants of survival following HIV-1 seroconversion after the introduction of HAARTLancet20033621267127414575971
   PubMed Web of Science ®Google Scholar
• BangsbergDRAcostaEPGuptaRAdherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessAIDS20062022323116511415
   PubMed Web of Science ®Google Scholar
• ShuterJForgiveness of non-adherence to HIV-1 antiretroviral therapyJ Antimicrob Chemother20086176977318256112
   PubMed Web of Science ®Google Scholar
• BangsbergDRPerrySCharleboisEDNon-adherence to highly active antiretroviral therapy predicts progression to AIDSAIDS2001151181118311416722
   PubMed Web of Science ®Google Scholar
• Garcia de OlallaPKnobelHCarmonaAGuelarALópez-ColomésJLCaylàJAImpact of adherence and highly active antiretroviral antiretroviral therapy on survival in HIV-infected patientsJ Acquir Immune Defic Syndr20023010511012048370
   PubMed Web of Science ®Google Scholar
• Italian Ministry of Health – Centro Nazionale AIDS[Italian guidelines on the use of antiretroviral drugs and the diagnostic-clinical management of HIV-infected patients]2012 Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1793_allegato.pdfAccessed June 28, 2013 Italian
   Google Scholar
• RizzardiniGBonfantiPCarenziLCost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern ItalyTher Clin Risk Manag2012837738423028230
   PubMed Web of Science ®Google Scholar
• CastagnaAColomboGSalpietroSGalliLPoliALazzarinACost-effectiveness evaluation of initial HAART regimens for managing HIV-infected patients according to real clinical practiceJ Int AIDS Soc201215 Suppl 418386
   Google Scholar
• MaggioloFDi MatteoSMasiniGCost-effectiveness analysis of first-line HAARTJ Int AIDS Soc201215 Suppl 418377
   Google Scholar
• European Medicines AgencyEviplera – key facts2011 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002312/smops/Positive/human_smop_000277.jsp&mid=WC0b01ac058001d127&murl=menus/medicines/medicines.jspAccessed June 28, 2013
   Google Scholar
• Italian Medicines Agency (AIFA)- Reimbursement and price of the medicinal products Eviplera - Regime di rimborsabilità e prezzo di vendita del medicinale per uso umano Eviplera (emtricitabina/tenofovir disoproxil/rilpivirina) autorizzata con procedura centralizzata europea dalla Commissione EuropeaBoll Mens Stat (Rome)2013352425 Available from: http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2013-02-11&atto.codiceRedazionale=13A00956&elenco30giorni=trueAccessed June 28, 2013 Italian
   Google Scholar
• ColomboGLColangeliVDi BiagioADi MatteoSViscoliCVialePCost-effectiveness analysis of initial HIV treatment under Italian guidelinesClinicoecon Outcomes Res2011319720522163167
   PubMedGoogle Scholar
• Italian Ministry of Health[Italian guidelines on the use of antiretroviral drugs and the diagnostic-clinical management of HIV-infected patients]. Commissione Nazionale per la lotta contro l’AIDS. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-12010 Available from: http://www.ristretti.it/commenti/2010/luglio/pdf4/linee_hiv_carcere.pdfAccessed June 28, 2013 Italian
   Google Scholar
• Fondazione ICONA – Italian Cohort Naive Antiretrovirals- Patients with very high pre-HAART viremia are at highest risk of experiencing virological rebound Available from: http://www.fondazioneicona.org/_new/download/home/icar2013/Armenia.pdfAccessed June 28, 2013
   Google Scholar
• Regione Emilia-RomagnaThe state of HIV/AIDS infection in Emilia-Romagna Available from: http://www.epicentro.iss.it/regioni/emilia/pdf/ER_Hiv-Aids08.pdfAccessed June 28, 2013 Italian
   Google Scholar
• SimpsonKNLuoMPChumneyESunEBrunSAshrafTCost-effectiveness of lopinavir/ritonavir versus nelfnavir as the first-line highly active antiretroviral therapy regimen for HIV infectionHIV Clin Trials2004529430415562370
   PubMed Web of Science ®Google Scholar
• PezzottiPAngelettiCThe determinants of spending on antiretrovirals: a budget impact analysis model based on regional data2010 Available from: http://www.asplazio.it/asp_online/prev_for_doc/files/formazione/aids/11/modulo_01/Pezzotti_11.pdfAccessed June 28, 2013 Italian
   Google Scholar
• Italian Health Economics Association (AIES)Italian guidelines proposal on how to conduct economic evaluation studies of health programsPharmacoecon Ital Res Artic2009118393 Italian
   Google Scholar
• CohenCWohlDArribasJSTAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adultsJ Int AIDS Soc201215 Suppl 418221
   Google Scholar
• CohenCJMolinaJMCahnPEfficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsJ Acquir Immune Defic Syndr201260334222343174
   PubMed Web of Science ®Google Scholar
• DaarETierneyCFischlMACTG 5202: Final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patientsPresented at: 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)February 16–19, 2010San Francisco, CA
   Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS2009231679168819487905
   PubMed Web of Science ®Google Scholar
• OrkinCDeJeesusEKhanlouHARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) versus lopinavir/r (LPV/r) in treatment-naive HIV-1-infected adultsJ Int AIDS Soc201013 Suppl 4P3
   Google Scholar
• EronJJJrRockstrohJKReynesJRaltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialLancet Infect Dis20111190791521933752
   PubMed Web of Science ®Google Scholar
• RockstrohJKLennoxJLDeJesusELong-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKClin Infect Dis20115380781621921224
   PubMed Web of Science ®Google Scholar
• LennoxJLDeJesusELazzarinASafety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLancet200937479680619647866
   PubMed Web of Science ®Google Scholar
• RockstrohJKDeJesusELennoxJLYazdanpanahYSaagMSWanHRodgersAJWalkerMLMillerMDiNubileMJNguyenBYTepplerHLeavittRSklarPSTARTMRK InvestigatorsDurable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJ Acquir Immune Defic Syndr2013May 1631778523412015
   PubMed Web of Science ®Google Scholar
• MolinaJMCahnPGrinsztejnBRilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialLancet201137823824621763936
   PubMed Web of Science ®Google Scholar
• CohenCJAndrade-VillanuevaJClotetBRilpivirine versus efa-virenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialLancet201137822923721763935
   PubMed Web of Science ®Google Scholar
• FourieJFlammJRodriguez-FrenchAEffect of baseline characteristics on the efficacy and safety of once-daily darunavir/ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96HIV Clin Trials20111231332222189150
   PubMed Web of Science ®Google Scholar
• Lombardy Region, Decree-Law n. 1725, DECRETO n. 1725 del 01/03/2013 [webpage on the Internet] Therapeutic diagnostic Path of patients with HIV disease Available from: http://www.sanita.regione.lombardia.it/cs/Satellite?c=Page&childpagename=DG_Sanita/Page/NormativaDetail&pagename=DG_SANWrapper&cid=1213275902673&keyid=4300Accessed June 28, 2013 Italian
   Google Scholar
• RizzardiniGRestelliUBonfantiPCost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?Clinicoecon Outcomes Res2012424525222973114
   PubMedGoogle Scholar
• JonssonBChanging health environment: the challenge to demonstrate cost-effectiveness of new compoundsPharmacoeconomics200422 Suppl 451015876007
   PubMed Web of Science ®Google Scholar
• LucioniCRavasioRHow to evaluate the results of a pharmacoeconomic study? Come valutare i risultati di uno studio farmacoeconomico?Pharmacoecon Ital Res Artic2004121130 Italian
   Google Scholar
• MessoriASantarlasciBTrippoliSVaianiMClinical benefit and economic value: methodology and economic application. Controvalore economico del farmaco e beneficio clinico:Stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomicoPharmacoecon Ital Res Artic200355367 Italian
   Google Scholar
• MoeremansKAnnemansLLöthgrenMCost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor- experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UKPharmacoeconomics201028 Suppl 110712821182347
   PubMed Web of Science ®Google Scholar
• MaggioloFRavasioLRipamontiDSimilar adherence rates favour different virologic outcomes for patients treated with non-nucleoside analogues or protease inhibitorsClin Infect Dis20054015816315614706
   PubMed Web of Science ®Google Scholar
• DeschampsAEDe GraeveVVan WijngaerdenEPrevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring SystemAIDS Patient Care STDS20041864465715633262
   PubMed Web of Science ®Google Scholar
• DiabateSAlaryMKoffiCKDeterminants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d’IvoireAIDS2007211799180317690579
   PubMed Web of Science ®Google Scholar
• StoneVEJordanJTolsonJMillerRPilonTPerspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherenceJ Acquir Immune Defic Syndr20043680881615213564
   PubMed Web of Science ®Google Scholar
• LimaVDHarriganRBangsbergDRThe combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over timeJ Acquir Immune Defic Syndr20095052953619223785
   PubMed Web of Science ®Google Scholar
• SaxPEMeyersJLMugaveroMDavisKLAdherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United StatesPLoS One20127e3159122384040
   PubMed Web of Science ®Google Scholar
• SterrantinoGSantoroLBartolozziDTrottaMZaccarelliMSelf-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART eraPatient Prefer Adherence2012642743322723727
   PubMed Web of Science ®Google Scholar
• AntinoriAMarcotullioSAmmassariAItalian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011New Microbiol20123511315922707127
   PubMed Web of Science ®Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• D’Arminio MonforteALepriACRezzaGInsights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve PatientsAIDS20001449950710780712
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med2000133213010877736
   PubMed Web of Science ®Google Scholar
• AntinoriACozzi-LepriAAmmassariARelative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAARTAntivir Ther2004929129615134192
   PubMed Web of Science ®Google Scholar
• ColomboGLGaetaGBViganòMDi MatteoSA cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in ItalyClinicoecon Outcomes Res20113374621935331
   PubMedGoogle Scholar
• JohnsonLFWhitePJA review of mathematical models of HIV/AIDS interventions and their implications for policySex Transm Infect20118762963421685191
   PubMed Web of Science ®Google Scholar